Advanced

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Pakpoor, Julia; Disanto, Giulio; Altmann, Daniel R; Pavitt, Sue; Turner, Benjamin P; Marta, Monica; Juliusson, Gunnar LU ; Baker, David; Chataway, Jeremy and Schmierer, Klaus (2015) In Neurology: Neuroimmunology and NeuroInflammation 2(6). p.158-158
Abstract
To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS).
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Neurology: Neuroimmunology and NeuroInflammation
volume
2
issue
6
pages
158 - 158
publisher
Wolters Kluwer Health/LWW
external identifiers
  • pmid:26468472
  • scopus:84952880790
ISSN
2332-7812
DOI
10.1212/NXI.0000000000000158
language
English
LU publication?
yes
id
d183cc1b-d188-474e-bd70-507a13356a84 (old id 8152227)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26468472?dopt=Abstract
date added to LUP
2015-11-03 14:00:51
date last changed
2017-11-19 03:48:23
@article{d183cc1b-d188-474e-bd70-507a13356a84,
  abstract     = {To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS).},
  author       = {Pakpoor, Julia and Disanto, Giulio and Altmann, Daniel R and Pavitt, Sue and Turner, Benjamin P and Marta, Monica and Juliusson, Gunnar and Baker, David and Chataway, Jeremy and Schmierer, Klaus},
  issn         = {2332-7812},
  language     = {eng},
  number       = {6},
  pages        = {158--158},
  publisher    = {Wolters Kluwer Health/LWW},
  series       = {Neurology: Neuroimmunology and NeuroInflammation},
  title        = {No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.},
  url          = {http://dx.doi.org/10.1212/NXI.0000000000000158},
  volume       = {2},
  year         = {2015},
}